For the Inventor, By the Inventor

Enter assignee name

Crystal Pharmatech Co., Ltd.

USPTO Granted Patents = 22

% Expired Patents = 68.2

CIPO Patents = 6

EPO Patents = 12

Trademarks = 1

Forward Citations = 36

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Yanfeng Zhang (22 out of 59 patents)

Minhua Chen (22 out of 57 patents)

Xiaoyu Zhang (20 out of 45 patents)

4. Chaohui Yang (6 out of 16 patents)

5. Xiaojuan Diao (6 out of 6 patents)

6. Jiaoyang Li (4 out of 5 patents)

7. Pixu Li (3 out of 11 patents)

8. Kai Liu (3 out of 34 patents)

9. Nan Xia (3 out of 6 patents)

10. Peng Wang (3 out of 12 patents)

11. Liang Zhang (3 out of 130 patents)

12. Po Zou (2 out of 6 patents)

13. Qiyue Liu (1 out of 3 patents)

14. Jinqiu Wang (1 out of 5 patents)

15. Shu Yu (1 out of 5 patents)

22 patents: Sort by Forward Citations

1. 10577334 - Crystalline form E of tafamidis meglumine, process for preparation and use thereof (2020-03-03),

2. 10562855 - Crystalline form of lenvantinib mesylate and process of preparation thereof (2020-02-18),

3. 10544129 - Crystalline forms of AP26113, and preparation method thereof (2020-01-28),

4. 10508087 - Crystalline forms of trisodium supramolecular complex comprising valsartan and AHU-377 and methods thereof (2019-12-17),

5. 10487064 - Crystalline forms of selective S1P1 receptor modulator and preparation method thereof (2019-11-26),

6. 10472369 - Crystalline forms of (6-(1H-indazol-6-yl)-N-[4-(4-(4-morpholinyl)phenyl]imidazo[1,2-A]pyrazin-8-amine) methanesulfonate (2019-11-12),

7. 10442775 - Preparation method for eutectic hydrate crystal form II of AHU-377 and diovan trisodium salt (2019-10-15),

8. 10377757 - Crystal form of JAK inhibitor and preparation method thereof (2019-08-13),

9. 10351536 - Crystalline forms of lesinurad and its sodium salt (2019-07-16),

10. 10323035 - Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof (2019-06-18),

11. 10308641 - Crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxole-5-yl)cyclopropane formamido)-3-methylpyridine-2-yl)benzoic acid and preparation method thereof (2019-06-04),

12. 10273262 - Crystalline form A of obeticholic acid and preparation method thereof (2019-04-30),

13. 10266523 - Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4'-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof (2019-04-23),

14. 10246437 - Crystal form of neratinib maleate and preparation method therefor (2019-04-02),

15. 10246418 - Crystal form of lenvatinib methanesulfonate salt and preparation method thereof (2019-04-02),

Company Overview

Crystal Pharmatech Co., Ltd. is a prominent player in the pharmaceutical and biotechnology sectors, specializing in the development and manufacturing of advanced drug delivery systems and formulation technologies. The company focuses on providing innovative solutions that enhance the efficacy and safety of pharmaceutical products. Based in Suzhou, China, Crystal Pharmatech leverages its expertise in research and development to support clients in navigating the complexities of drug formulation and regulatory compliance.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

22 Patents

#18 in Suzhou

#1,330 in China

#28,782 in the World

Crystal Pharmatech Co., Ltd.

Forward Citations = 36

17 inventors:

Yanfeng Zhang (22 out of 59 patents)

Minhua Chen (22 out of 57 patents)

Xiaoyu Zhang (20 out of 45 patents)

4. Chaohui Yang (6 out of 16 patents)

5. Xiaojuan Diao (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Crystal Pharmatech Co., Ltd.. Retrieved from https://idiyas.com/company/crystal-pharmatech-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…